China National Accord Medicines Corporation Ltd. announced unaudited earnings results for the quarter and nine months ended September 30, 2018. For the quarter, the company reported operating income of RMB 10,987,540,368.77, increased 2.17%. Net profit attributable to shareholders of the listed company was RMB 285,244,535.54, increased 15.49%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 282,319,350.57, increased 15.27%. Diluted earnings per share was RMB 0.666, increased 15.42%. Weighted average ROE was 2.62%, decreased by 0.13 percentage points. For the nine months, the company reported operating income was RMB 31,766,707,068.44, increased 1.56%. Net profit attributable to shareholders of the listed company was RMB 926,971,570.47, increased 15.42%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 905,615,689.91, increased 14.46%. Diluted earnings per share was RMB 2.165, increased 15.41%. Net cash flow arising from operating activities was RMB 563,991,295.36, increased 10.35%. Weighted average ROE was 9.21%, increased by 0.06 percentage points.